1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Post-SRS complications in patients with VS
Post-SRS Complication/Adverse Effects Reported Incidence Risk/Prognostic Factors
Vertigo and disequilibrium 1%–2% Marginal dose <13 Gy; larger tumors; female sex associated with worse outcomes
Facial nerve dysfunction <1% Younger patients, smaller tumors <1.5 cm³, and radiation dose <13 Gy associated with better outcomes
Trigeminal nerve dysfunction 3% at 5 years Total dose >13 Gy; brainstem dose >10 Gy; larger tumor volume associated with worse outcomes
Worsening hearing loss 21%–59% at 5 years Cochlear dose >4 Gy; marginal dose >13 Gy associated with worse outcomes
Hydrocephalus 2%–3% Older than 60 years of age; female sex; larger tumors associated with worse outcomes
Malignant transformation <0.04% at 15 years Underlying neurofibromatosis associated with increased incidence